NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 200
- Registration Number
- NCT00130364
- Locations
- 🇺🇸
This study is not being conducted in the United States, Novartis Pharmaceuticals, New Jersey, United States
A 3-week Study Investigating Patient Use and Functionality of Formoterol in a Novel Inhalation Device in Patients With Asthma
- Conditions
- First Posted Date
- 2005-08-15
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 155
- Registration Number
- NCT00130351
- Locations
- 🇺🇸
The Asthma & Allergy Center, PC, Papillion, Nebraska, United States
🇺🇸Allergy and Asthma Medical Group & Research Center, San Diego, California, United States
🇺🇸Clinical Research Institute, Minneapolis, Minnesota, United States
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
- Conditions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2012-04-27
- Lead Sponsor
- Novartis
- Registration Number
- NCT00129818
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸IU Center for Clinical STD Research, Indianapolis, Indiana, United States
Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 6
- Registration Number
- NCT00129831
- Locations
- 🇺🇸
Radiant Research, Boise, Idaho, United States
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
- Conditions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Novartis
- Target Recruit Count
- 130
- Registration Number
- NCT00128544
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients
- Conditions
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2012-04-30
- Lead Sponsor
- Novartis
- Target Recruit Count
- 100
- Registration Number
- NCT00128232
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 440
- Registration Number
- NCT00128245
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
- Conditions
- Interventions
- First Posted Date
- 2005-08-05
- Last Posted Date
- 2008-01-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 395
- Registration Number
- NCT00127270
- Locations
- 🇺🇸
Research Protocol Management Specialists, Pittsburgh, Pennsylvania, United States
🇺🇸Southern Oregon Health and Wellness, Medford, Oregon, United States
🇺🇸Urologic Surgery Associates, Overland Park, Kansas, United States
Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects
- Conditions
- First Posted Date
- 2005-08-01
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 98
- Registration Number
- NCT00125346
- Locations
- 🇲🇽
For information on a site near you, call 1-800-244-7668 Option "2", Tijuana, Mexico
Fluvastatin in Adults With Dislipidemia With History of Muscle Problems
- Conditions
- First Posted Date
- 2005-07-29
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 218
- Registration Number
- NCT00125125
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States